Dear editor,

We read with great interest the recent article published by Macro Zuin et al. in this journal suggested the prevalence of hypertension and its contribution to increased mortality risk in COVID-19 patients.[@bib0001] RAAS inhibitors is one of the commonly used medication for hypertension management. However, since the culprits of COVID-19, SARS-COV-2, takes advantage of membrane-bound angiotensin-converting enzyme 2 (ACE2) to infect host cells,[@bib0002] and which were reported to be upregulated in result of treatment of RAAS inhibitors,[@bib0003] ^,^ [@bib0004] concerns of using RAAS inhibitors in COVID-19 patients with hypertension were aroused. Nonetheless, in animal models of acute lung injury and other influenza virus infection, ACEI and ARB are protective by inhibiting the downregulation of ACE2 and further limit disease progression.[@bib0005] ^,^ [@bib0006] Thus, RAAS inhibitors might be theoretically protective in patient with COVID-19. Despite various studies showed that RAAS inhibits were not harmful in COVID-19,[@bib0007] ^,^ [@bib0008] more clinical data and evidence are needed for clarifying this controversial issue and developing better treatment plans for patients suffering COVID-19.

Here, we present a retrospective study, analyzing use of different antihypertensive drugs and its association with various outcomes of COVID-19 patients with hypertension. Overall, 971 hypertensive patients among 2044 participants discharged or died in two campuses of Tongji hospitals, Wuhan, the Sino-French New City Campus, and the Optical Valley Campus, from January 27th to March 21st were enrolled (Fig. S1).

In this study, 733 (75.49%) patients with hypertension had at least one of the five categories of antihypertensive medications (ACEI, ARB, beta-blocker, CCBs, and diuretic), and 233 (24.51%) patients with hypertension had none of them (Table S1). Among the 733 patients, 27 (3.68%) and 169 (23.06%) patients used ACEIs and ARBs, respectively. CCBs were most used since 589 (80.35%) patients took these agents. 733 patients were classified according to the antihypertensive medications they received. Considering there were 27 cases in ACEI group and use of ACEI and ARB had no substantial difference in all aspects of comparison (Table S2), the two groups were merged into ACEI/ARB (RAAS inhibitors) group for later analysis.

In logistic regression model adjusted by propensity score, use of RAAS inhibitors, beta-blockers, and CCBs showed no significant difference (Table S3). And use of diuretics was associated with higher risk of cardiac injury (OR=2.65, 1.25--5.62, *p* = 0.011) vs. use of non-diuretics. Parameters for adjusting were listed in supplementary materials.

To have a more overall estimation, we further compared the risk of various outcomes between 233 patients in uncontrol group, who did not have antihypertensive drugs during hospitalization, and patients in medication group. As shown in [Table 1](#tbl0001){ref-type="table"} , patients who used beta-blockers, CCBs, and diuretics exhibited no significant difference compared with uncontrol group. However, patients used RAAS inhibitors had lower risk of death (OR=0.26, 0.08--0.80, *p* = 0.019), ICU admission (OR=0.21, 0.05--0.99, *p* = 0.049), and septic shock (OR=0.34, 0.12--0.99, *p* = 0.047).Table 1Odds ratio for variable outcomes of patients who received RAAS inhibitors and those in uncontrol group.Table 1ACEI/ARB (*N* = 196) vs. Uncontrol (*N* = 233)Beta--blocker (*N* = 248) vs. Uncontrol (*N* = 233)CCB (*N* = 589) vs. Uncontrol (*N* = 233)Diuretics (*N* = 56) vs. Uncontrol (*N* = 233)OR (95%CI)*p*OR (95%CI)*p*OR (95%CI)*p*OR (95%CI)*p*COVID--19 critic, *n*(%)0.43(0.17--1.06)**0.080**0.80(0.40--1.57)**0.509**0.84(0.48--1.47)**0.539**0.75(0.13--4.51)**0.755**Sepsis, *n*(%)1.29(0.72--2.31)**0.387**1.46(0.85--2.51)**0.171**1.23(0.79--1.92)**0.351**1.27()0.37--4.36**0.707**Septic shock, *n*(%)0.34(0.12--0.99)**0.047**0.69(0.34--1.40)**0.300**0.85(0.47--1.54)**0.598**0.81(0.13--4.90)**0.821**Respiratory failure, *n*(%)0.47(0.16--1.04)**0.059**0.75(0.38--1.46)**0.392**0.81(0.47--1.40)**0.444**0.91(0.18--4.51)**0.906**ARDS, *n*(%)1.07(0.57--2.03)**0.831**1.13(0.63--2.03)**0.670**1.15(0.70--1.87)**0.579**1.57(0.43--5.78)**0.495**Heart failure, *n*(%)0.98(0.36--2.70)**0.974**0.92(0.43--2.00)**0.840**0.69(0.351.37)**0.294**0.66(0.06--7.10)**0.731**Coagulopathy, *n*(%)1.12(0.47--2.67)**0.805**0.95(0.50--1.82)**0.874**0.97(0.54--1.73)**0.909**0.53(0.05--5.23)**0.589**Cardiac injury, *n*(%)1.67(0.84--3.34)**0.146**1.59(0.90--2.85)**0.114**0.96(0.59--1.56)**0.871**2.58(0.68--9.71)**0.162**Kidney injury, *n*(%)0.67(0.31--1.44)**0.307**0.62(0.32--1.21)**0.158**0.73(0.43--1.22)**0.229**0.68(0.015--3.13)**0.623**Liver injury, *n*(%)1.13(0.632.02)**0.680**1.06(0.61--1.83)**0.832**1.15(0.74--1.80)**0.534**0.83(0.23--3.05)**0.779**Hypoproteinemia, *n*(%)0.84(0.44--1.61)**0.599**0.89(0.50--1.60)**0.701**0.88(0.54--1.44)**0.616**0.88(0.21--3.78)**0.864**Secondary infection, *n*(%)3.27(0.23--47.90)**0.384**5.32(0.53--53.42)**0.156**3.99(0.32--49.07)**0.279**\_\_\_*\_\_\_*ICU admission, *n*(%)0.21(0.05--0.99)**0.049**0.57(0.25--1.34)**0.198**0.85(0.43--1.65)**0.621**0.49(0.05--4.91)**0.543**Death, *n*(%)0.26(0.08--0.80)**0.019**0.60(0.29--1.24)**0.167**0.68(0.38--1.22)**0.192**0.31(0.03--3.00)**0.310**[^2][^3]

Then, we took a closer look at ACEI/ARB group and uncontrol group. These two groups were imbalanced in some baseline characteristics, as shown in Table S4. To eliminate the distractions of confounding factors, we introduced coarsened exact matching to get a proper cohort for further analysis. The matching parameters included age, sex, history of chronic cardiovascular disease, and severity of disease at admission. 130 patients were successfully matched in ACEI/ARB group to uncontrol group at a ratio of 1:1, and baseline characteristics of matched patients were shown in Table S4. The treatments patients received in hospital in two groups were similar in matched groups (Table S5). After matching, results were even more encouraging, use of RAAS inhibitors was associated with remarkably lower mortality (4.62% vs. 16.92%, *p* = 0.001) than uncontrol group ([Table 2](#tbl0002){ref-type="table"} and Fig. S2). And the rate of septic shock and heart failure were 2.86 times lower (5.38% vs. 15.38%, *p* = 0.008) and 2.62 times lower (3.85% vs. 10.08%, *p* = 0.049) in ACEI/ARB group than uncontrol group, respectively. As of outcomes of respiratory system, 9.23% of patients in ACEI/ARB group progressed into respiratory failure, by contrast with 20.00% in uncontrol group (*p* = 0.014). For ARDS, numbers of case in both groups were 33. As for the highest level of disease severity during patients' hospitalization, 7.69% of patients in AECI/ARB group were classified as critically ill, while 19.23% in uncontrol group (*p* = 0.012). And maximum SOFA score of 13.08% of patients were rated as level 2, while 19.23% in uncontrol group (*p* = 0.045).Table 2Various outcomes of patients in ACEI/ARB group and uncontrol group after matching.Table 2Uncontrol (*N* = 130)ACEI/ARB (*N* = 130)Total (*N* = 260)*p*Maximum severity of COVID--19 during hospitalization, *n*(%)General59(45.38)58(44.62)117(45)**0.012**Severe46(35.38)62(47.69)108(41.54)Critic25(19.23)10(7.69)35(13.46)Maximum of SOFA score, *n*(%)083(63.85)75(57.69)158(60.77)**0.045**122(16.92)38(29.23)60(23.08)225(19.23)17(13.08)42(16.15)Maximum of SOFA score1(0--3)1(0--2)1(0--2)**0.8958**Onset to ICU, day12(62--24)21(18--27)18.5(9--25)**02361**Onset to discharge, day32(24--39)35(29--47)33.5(26--42)**0.0003**ICU length, day8(3--13)7(6--8)7.5(3--9)**0.7283**Viral duration, day23.5(17--30.5)26(19--31)24(18--31)**0.1782**Sepsis, *n*(%)46(35.38)53(40.77)99(38.08)**0.371**Septic shock, *n*(%)20(15.38)7(5.38)27(10.38)**0.008**Respiratory failure, *n*(%)26(20.00)12(9.23)38(14.62)**0.014**ARDS, *n*(%)33(26.38)33(25.38)66(25.38)**1.000**Heart failure, *n*(%)13(10.08)5(3.85)18(6.95)**0.049**Coagulopathy, *n*(%)18(13.85)9(6.92)27(10.38)**0.067**Cardiac injury, *n*(%)26(22.81)35(28.93)61(25.96)**0.285**Kidney injury, *n*(%)25(19.23)15(11.54)40(15.38)**0.086**Liver injury, *n*(%)43(33.08)57(43.85)100(38.46)**0.074**Hypoproteinemia, *n*(%)35(26.92)37(28.46)72(27.69)**0.782**Second infection, *n*(%)0(0.00)1(0.77)1(0.38)**1.000**ICU admission, *n*(%)13(10.00)5(3.85)18(6.92)**0.051**Death, *n*(%)22(16.92)6(4.62)28(10.77)**0.001**Hospitalization time of survivals [†](#tb2fn1){ref-type="table-fn"}, day18(11--24)23(16.5--30.5)20(14--27.5)**\<0.0001**Hospitalization time of victim[§](#tb2fn2){ref-type="table-fn"}, day7.5(5--15)14(8--19)8.5(5--17)**0.0764**Disease duration of survivals, day32(25--40)36(29--47)35(28--43)**0.004**Disease duration of victims, day21(16--32)23.5(20--27)23(16.5--30)**0.8008**[^4][^5][^6]

Our retrospective analysis implied that in-hospital use of ACEI/ARB was not substantially associated with higher risk of progressing into unfavorable outcomes. Furthermore, in comparison between patients who received a specific kind of antihypertensive medication and those who did not have any relative drugs administration, ACEI/ARB demonstrated a protective effect, while other three kinds of antihypertensive drugs did not exhibit obvious advantages. Besides, we found that patients in diuretics group had higher risk of cardiac injury than those had other antihypertensive agents administration, after ruling out the use of diuretics for purpose of reducing capacity and took history of cardiovascular disease into propensity score. The mechanism behind this association remained enigmas and needs further assessments.

There are several limitations of this study. First, our cases we collected were primarily Wuhan locals, so impact of races and geographical differences could not be reflected. Second, limited by the nature of retrospective research, medication extracted from electronic system may not match the actual drug use of some patients. Third, we did not take cigarette exposure history, psychological status, education level, and other social factors into analysis, which may impose influence on results.

In summary, despite that confounding factors not taken into analysis might contribute to the positive role ACEI/ARB played, we were confident to reach the conclusion that in-hospital use of ACEI/ARB was protective, instead of harmful, in COVID--19 patients with hypertension.
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[^2]: Abbreviations: ARDS: adult respiratory distress syndrome; ICU, intensive care unit.

[^3]: "\_\_\_" The number of cases was too small to analysis.

[^4]: Abbreviations: SOFA, Sequential Organ Failure Assessment.

[^5]: Hospitalization time of survivals was defined as the time from admission to hospital to discharge of patients who survived from COVID-19.

[^6]: Hospitalization time of victim was defined as the time from admission to hospital to death of patients who did not survived from COVID-19.
